Literature DB >> 30294914

A role for surgery in the treatment of relapsed Hodgkin lymphoma.

A S Fahy1, I Kong2, S Weitzman3, D Dix3, S Baruchel3, J T Gerstle1.   

Abstract

Treatment of Hodgkin lymphoma (HL) has advanced over time, rendering a fatal disease now largely curable. Multiagent chemotherapy regimens, hematopoietic stem cell transplantation, and radiotherapy are the mainstays of care. Surgical intervention is rarely indicated other than for biopsy at diagnosis. However, for patients with recurrent relapsed HL isolated to one anatomical location, refractory to all other therapy, there may be a beneficial role for surgical excision. Herein, we report the surgical management of three relapsed patients with stage IVB HL who were refractory to multiple other therapeutic approaches, who all achieved good event-free survival after operative management.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Hodgkin; excision; recurrent lymphoma; surgery

Mesh:

Year:  2018        PMID: 30294914     DOI: 10.1002/pbc.27402

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  1 in total

1.  Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin's Disease.

Authors:  Florian Lüke; Dennis C Harrer; Karin Menhart; Daniel Wolff; Ernst Holler; Dirk Hellwig; Wolfgang Herr; Matthias Grube; Martin Vogelhuber; Albrecht Reichle; Daniel Heudobler
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.